NDC product
Severe Nasal
NDC 73492-715 · ALAINA HEALTHCARE PRIVATE LIMITED
Key facts
| Product NDC | 73492-715 |
|---|---|
| Proprietary name | Severe Nasal |
| Nonproprietary name | oxymetazoline hydrochloride 0.05% |
| Substances | OXYMETAZOLINE HYDROCHLORIDE |
| Dosage form | SPRAY |
| Route | NASAL |
| Labeler | ALAINA HEALTHCARE PRIVATE LIMITED |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Imidazolines [CS], Increased Sympathetic Activity [PE], Vasoconstriction [PE], Vasoconstrictor [EPC] |
| Marketing start | Sep 15, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: